Genentech. Genentech shall maintain on an ongoing basis coverage for Products Liability and Completed Operations including coverage for Clinical Trials, in the minimum amount of [*****] per occurrence, combined single limit for bodily injury and property damage liability.
Genentech. Genentech shall require all of its employees, contractors and agents, and any Affiliates and Third Parties working on its behalf under this Agreement (and their respective employees, contractors and agents), to assign to Genentech any Program IP Rights and Genentech IP Rights, created, discovered, conceived or reduced to practice by such employees, contractors or agents or Affiliates or Third Parties.
Genentech. Genentech shall perform its obligations under each Research Program using such number of Genentech FTEs as it deems appropriate to conduct activities delegated to it under such Research Program.
Genentech. As between the Parties, Genentech shall solely own (a) the Genentech IP (other than Program IP) and (b) Genentech Core Inventions; and
Genentech. The chairman will call and chair meetings of the Joint Commercialization Committee which will be held at GENENTECH's facilities unless mutually agreed otherwise or by video conference where feasible.
Genentech. OSI/GNE JOINT STEERING COMMITTEE -------------------------------- US Development/Commercialization 3 Senior Managers Each -Guidance -Annual Plan and Budget Approval -------------------------------------------------- ----------------- Joint Finance Sub-Committee ----------------- ------------------------------------- OSI/GNE ---------- US PROJECT TEAM ------------------------------------- ------------------- CRO MANUFACTURING DATA, ETC. ------------------- -------------------- GNE Regulatory Affairs Clinical Sub-Committee R&D OSI Clinical Team -------------------- Activities Team
Genentech. In July 2016, the ECJ gave a ruling on a question from the Paris Court of Appeal as regards competition law and patent licences.101 The case arose from an arbitration which had been appealed to the French courts. Genentech had entered into a patent licensing agreement with Behringswerke, a company subsequently taken over by Sanofi-Aventis, for a worldwide non-exclusive licence to use a patented “cytomegalovirus enhancer” to make a product used for 91 Opinion of X.X. Xxxxxxxx in VM Remonts EU:C:2015:797. 92 Opinion of X.X. Xxxxxxxx in VM Remonts EU:C:2015:797 at [63]. 93 Opinion of X.X. Xxxxxxxx in VM Remonts EU:C:2015:797 at [65]. 94 Opinion of X.X. Xxxxxxxx in VM Remonts EU:C:2015:797 at [69]. 95 Opinion of X.X. Xxxxxxxx in VM Remonts EU:C:2015:797 at [70]. 96 Opinion of X.X. Xxxxxxxx in VM Remonts EU:C:2015:797 at [25]. 97 Opinion of X.X. Xxxxxxxx in VM Remonts EU:C:2015:797 at [27].
Genentech. Genentech hereby represents and warrants to Immunex that: ---------
Genentech. During the Term and for five (5) years thereafter, Genentech will obtain and maintain comprehensive general liability insurance including broad form general liability, completed operations and products liability, personal injury liability, blanket contractual liability and broad form property damage liability) with limits of not less than $5,000,000 combined single limit for bodily injury and property damage liability per occurrence and annual aggregate, containing a cross-liability or severability of interests clause. During the Term, Genentech will obtain and maintain worker's compensation insurance as required under applicable law and employer's liability insurance with a limit of not less than $1,000,000. With respect to all insurance coverage required under this SECTION 10.5(b): (i) all insurance carriers shall be reputable; (ii) Genentech will furnish Alkermes with certificates of insurance evidencing at least the required coverage as soon as practicable after the Effective Date and each anniversary of the Effective Date during the Term (and for five (5) years thereafter if such coverage is then required hereunder); and (iii) all policies will include provisions for at least ten (10) days' prior written notice of any material change or cancellation (whether for non-payment or otherwise).
Genentech. Genentech shall require all of its employees, contractors and agents, and any Affiliates and Third Parties working on its behalf under this Agreement (and their respective employees, contractors and agents), to assign to Genentech any Know-How and other intellectual property (together with all Patents and other intellectual property rights therein) developed, conceived, or reduced to practice by such employees, contractors or agents or Affiliates or Third Parties; provided, that, in the case of any such Third Parties, to the extent that an assignment of such intellectual property cannot be obtained, then (i) licenses sufficient to enable the Development, Commercialization and Manufacturing of Collaboration Constructs and Collaboration Products hereunder and, (ii) with respect to PD1 Component Know-How or IL-15 Component Know-How disclosed or claimed in any Xencor Non-Collaboration PD1/IL-15 Patent, and with respect to Xencor Non-PD1 Component IP, licenses sufficient to enable the Development, Commercialization and Manufacturing of any construct and any product for all uses, shall satisfy the obligations of this Section 10.3.2. Genentech hereby assigns to Xencor any and all rights, title, or interest that Genentech may have in any Xencor Core Invention and [***].
